In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to MedicinesNovember 15, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) believes that generic and biosimilar medicines can play a fundamental role in improving access to high quality medicines for patients worldwide. Read More
IGBA Joins ICH and Welcomes the Positive Vote of the General AssemblyGeneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements… Read More
Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines AgendaDubrovnik, 9 June 2016 – During the next two days, the key pharmaceutical industry leaders from the generic, biosimilar and value added medicines industries will meet in Dubrovnik to foster international partnership, cooperation and dialogue and discuss the most recent challenges… Read More